Shares of asset management holding company Janus Capital Group, Inc. (JNS) are up $4.44, or 39.65%, at $15.50, after the company this morning reported that Bill Gross, founder of bond giant PIMCO, has left his post as chief investment and joined Janus.
“Today, with a mixture of excitement and sadness, I am announcing that I have decided to join Janus Capital Group and end my association with PIMCO,” Gross said in a statement.
“But now, after having spent considerable time serving in senior management, it is a time for me to reduce executive and people management responsibilities at a larger firm and focus on the pure aspects of portfolio management at a smaller one. Janus is the right fit at the right time in my career – and my life.”
Janus said Gross will manage a recently launched Janus Global Unconstrained Bond Fund and related strategies, and will join Myron Scholes, Ph.D., and other members of the Janus team focused on global asset allocation. Mr. Gross’ employment will be effective September 29, 2014 and he will begin managing the Janus Global Unconstrained Bond Fund and related strategies effective October 6, 2014.
Shares of Digital Ally, Inc. (DGLY) are up $2.82, or 18.70%, at $17.90, after the company announced that it has received an order from a U.S. military base involving the company’s complete video evidence gathering system. The initial order is valued at approximately $200,000, with subsequent follow-on orders expected.
DGLY has a most recent quarter price-to-book and t-12 price-to-sales ratio of 6.59 and 2.66, respectively. EPS for the same period is ($1.98).
In the past 52 weeks, shares of Lenexa, Kansas-based firm have traded between a low of $3.03 and a high of $33.59. Shares are up 4.87% year-over-year and 64.09% year-to-date.
The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.
AcelRx Pharmaceuticals Inc (ACRX) is one of Friday’s notable stocks in decline, down 17.26% to $5.56. The nosedive came after the specialty pharmaceutical company provided an update on a recently held a teleconference with representatives from the Food and Drug Administration on the plans for the resubmission of the company’s New Drug Application (NDA) for Zalviso™.
“The discussion with the FDA was productive,” Richard King, president and CEO of AcelRx said in a press release.”Over the coming months we will prepare, submit and finalize with the FDA the protocols required to complete this work. Assuming timely review by the FDA on the protocols, we anticipate being able to complete the work with a target to refile the Zalviso NDA in the first quarter of 2015. However, depending on feedback from the FDA, the timing of the filing of the NDA could be later than the first quarter of 2015.”
In the past 52 weeks, shares of Redwood City, California-based firm have traded between a low of $6.04 and a high of $13.64. Shares are down 36.90% year-over-year and 40.58% year-to-date.
The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.
Shares of BlackBerry Limited (BBRY) are up almost 4%, at $10.16, after the company posted a loss of $207 million in Q2 on Friday, a much-smaller-than-expected quarterly loss, and its Chief Executive projected the tech Canadian company would report positive net income next fiscal year.
BBRY has T-12 price-to-sales ratio of 1.08. EPS for the same period is ($11.47). In the past 52 weeks, shares of BlackBerry maker have traded between a low of $5.44 and a high of $11.65. Shares are up 30.44% year-over-year and 39.38% year-to-date.
The chart below shows where the equity has traded over the last year, with the 50-day and 200-day moving averages included.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply